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Background: Breast cancer screening is offered to BRCA1 and BRCA2 mutation 
carriers from the age of 25 years because of their increased risk of breast cancer. As 
ovarian cancer screening is not effective, risk-reducing salpingo-oophorectomy 
(RRSO) is offered after child bearing age. RRSO before menopause reduces the 
breast cancer risk as well as breast density. It can be questioned whether after 
premenopausal RRSO, the intensive breast cancer screening program needs 
modification.
Methods: We evaluated the effectiveness of breast cancer screening by clinical 
breast examination (CBE), mammography, and MRI in a population of 88 BRCA1 
and 51 BRCA2 mutation carriers who had RRSO before the age of 52. Sensitivity, 
specificity, positive predictive value (PPV), and negative predictive value (NPV) 
were calculated for each screening modality.
Results: During 422 women years, 14 breast cancers were diagnosed; 2 prevalent, 
10 screen detected and 2 interval breast cancers (12 in BRCA1 and 1 in BRCA2 
mutation carriers). Sensitivity, specificity, PPV, and NPV for the combined 
screening were 85.7%, 97.6%, 30.0%, and 99.8%, respectively. No tumours were 
found with CBE, MRI had a sensitivity of 60.0% and mammography of 55.6%. Off 
all the tumours, 60% were node positive.
Conclusion: Effectiveness of CBE and mammography was comparable to earlier 
findings. MRI screening seemed less effective than earlier findings. After RRSO, 
the breast cancer risk in BRCA1 and BRCA2 mutation carriers is still high enough 
to justify intensive breast cancer screening with MRI and mammography.
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Introduction
Breast cancer is the most common cancer in women and the lifetime risk 
of developing breast cancer for individual women in western countries is 
approximately 12 – 13% (1). Women with a family history of breast and/or ovarian 
cancer can have substantially higher risks (42). For women with a proven BRCA1 
or BRCA2 mutation, life time risk can reach up to 65 – 80% for breast cancer 
and 45% for ovarian cancer by the age of 70 (5,6). In the Northern Netherlands 
we found a cumulative breast cancer risk of 71.4% (95% CI 67 – 82%) for BRCA1 
mutation carriers and 87.5% (95% CI 82 – 93%) for BRCA2 mutation carriers by age 
of 70. For ovarian cancer these risks were 58.9% (95% CI 54 – 64%) and 34.5% (95% 
CI 25 – 44%), respectively (4).
Female mutation carriers are counselled on different risk reducing strategies, 
e.g. screening or prophylactic surgery. Prophylactic mastectomy strongly reduces 
the breast cancer risk, with about 90% at the age of 70 when conducted at the 
age of 38 years (183,244). Intensive breast cancer screening in mutation carriers 
consists of annual MRI, mammography, and clinical breast examination (CBE) 
and can reach a sensitivity of more than 90% in finding early stage breast cancer 
in mutation carriers (163,170,173,175,245). For ovarian cancer, it was recently 
shown that current screening protocols are ineffective in detecting early stage 
ovarian cancer in mutation carriers and the only effective strategy to prevent 
ovarian cancer death is a risk reducing salpingo-oophorectomy (RRSO), which is 
eventually chosen by approximately 70% of these women (27,28,246,247).
When this procedure is performed before the age of 50 years, the risk of breast 
cancer is also reduced, with up to 50%, depending on the timing of RRSO (31). 
Nevertheless, breast cancer screening before the age of 50 is indicated for women 
with a breast cancer risk that is three times higher than the population risk 
(159,248). BRCA1 and BRCA2 mutation carriers continue to receive the same three 
modality breast screening program after RRSO as they had before.
Intensive breast cancer screening combining MRI, mammography, and CBE 
was proven to be effective in women at high risk for breast cancer (163,170,173,175). 
One of the reasons that MRI was introduced in the screening program is that 
mammography is less effective in younger premenopausal women with higher 
breast density, as is the case in BRCA1/2 mutation carriers. We hypothesize that 
the breast cancer screening protocol might need adaptation in women after 
RRSO, because of the lower breast cancer incidence and the lower breast density 
after surgical menopause. The aim of this study is therefore to determine the 





To determine the effectiveness of breast cancer screening in BRCA1/2 mutation 
carriers after RRSO, a retrospective cohort study was performed in BRCA1 
or BRCA2 mutation carriers who underwent a RRSO. All women who were 
younger than 52 years of age at RRSO (which is the mean age at menopause the 
Netherlands) were included. Results from subsequent breast cancer screening 
visits at the family cancer clinic from the University Medical Center Groningen 
(UMCG) between January 1995 and the end of September 2009 were analysed. 
Women needed to have at least one breast eligible for screening. Women with 
uni- or bilateral breast conserving therapy were included. The use of hormonal 
replacement therapy (HRT) was recorded and this was not an exclusion criterion. 
Women in whom ovarian cancer was diagnosed during RRSO were not included 
in the study.
Surveillance protocol
In our family cancer clinic, RRSO was initially an option from the age of 35 – 
40 years in BRCA1 mutation carriers and from the age of 40 – 45 years in BRCA2 
mutation carriers. As of 2007, counselling has moved toward a specific advice 
to have RRSO around the age of 40, because ovarian screening appeared not 
effective in reducing ovarian cancer death (27,28). However, the actual timing of 
this decision depends on many personal circumstances such as previous breast 
cancer, marital status, previous or planned pregnancies, and mental acceptance 
of this definitive procedure. The operative procedure is a day care surgical 
procedure, performed by laparoscopy (35).
As of 1995, annual clinical breast examination (CBE) by oncologic surgeons 
and nurse practitioners was performed together with annual mammography 
from the age of 25. From 1999, annual MRI was added to the protocol in a part 
of our population that participated in the MRISC study (163,164). After 2005 it is 
advised to screen BRCA1/2 mutation carriers with annual CBE and MRI from age 
25 till 60, to which mammography is added from age 30 onwards (159,248). At 
our centre, MRI and mammography imaging is ideally performed alternating, 
i.e. with a 6 month interval.
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Variables and endpoints
Information on date of birth, mutation status, personal oncologic history, date 
of RRSO, and HRT use were collected for all women. For previous breast cancers, 
we collected information about age at diagnosis and therapy. We reviewed every 
visit were CBE, mammography and/or MRI was performed. For all these visits, 
the reason for visiting (screening or interval visit due to signs or symptoms), 
the performed diagnostic procedures and the outcomes of these investigations 
were collected. The result of a CBE consult is considered possibly malignant in 
case of referral for further investigation. The results of mammography and MRI 
screening are scored in a standardized way, according to the Breast Imaging 
Reporting and Data System (BI-RADS) classification. BI-RADS categories vary 
between 0 and V and BI-RADS category III or higher are considered abnormal 
and indicate further analysis by ultrasound, MRI and/or tissue sampling (249-
251).
When additional diagnostic procedures were performed, the type of 
procedure and the findings were noted. Findings could be “no malignancy” 
(when no malignancy was found at the additional diagnostic procedures), 
“suspect for malignancy” (when more additional investigation was necessary), 
and "malignancy” (as confirmed by biopsy). For each new breast cancer, tumour 
size in millimetres and the presence or absence of lymph node metastases in the 
(sentinel) axillary lymph nodes were noted.
Data collection
All relevant data were retrieved from the patients’ hospital file. Physician’s letters, 
pathology reports, and imaging reports were used to collect detailed information 
about above mentioned variables and endpoints as defined below. Data from 
all consecutive screening visits after RRSO were entered into an SPSS database. 
Protection of the patient’s identity was guaranteed by a patient identification 
number. Those numbers were only retraceable to an individual woman when 
entered in the hospital database, which is only accessible for medical staff from 
the hospital, having a personal account. Complying with Dutch law, no further 
Institutional Review Board approval was needed.
Statistical analysis
Duration of follow-up was calculated for each woman. Follow-up time was 
calculated from the date of RRSO to the following endpoints: date of prophylactic 
mastectomy, date of ablation or date of last screening visit. Newly detected 
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malignancies were defined as prevalent, screen-detected, or interval cancers. 
Women were assigned to two groups, based on their mutation (BRCA1 or BRCA2). 
Characteristics of women are presented with median and range when they are 
continuous variables. For the other variables numbers are given and percentage 
for each mutation group. Differences between groups were calculated with the 
Kruskall Wallis test for continuous variables and χ2 tests for the percentages 
within mutation groups. To compare the three different screening modalities, we 
calculated the sensitivity, specificity, PPV, and NPV of each screening modality. 
For these four outcomes, 95% confidence interval (95% CI) was calculated with 
the Wilson score interval method. For MRI and mammography, calculations 
were made for BI-RADS III and IV as cut off point for a positive (suspect) test. 
Statistical analyses were performed using the software of SPSS 16.0 for Windows 
and the VassarStats website (252).
Results
Population characteristics
Of all the mutation carriers who were screened at the UMCG after RRSO during 
the study period, 139 women met our inclusion criteria; 88 (63.3%) BRCA1 mutation 
carriers and 51 (36.7%) BRCA2 mutation carriers (Table 2.1). BRCA1 mutation carriers 
had a median age at RRSO of 40.5 years (range 30–51 years) and BRCA2 mutation 
carriers had a median age of 42 years (range 33 – 51 years). Of all women, 18% 
had a history of breast cancer, BRCA1 mutation carriers more often than BRCA2 
mutation carriers (22.7% and 9.8%, respectively, p = 0.081). Of all women, BRCA1 
mutation carriers reported significantly more often breast cancer before and at 
the age of 45 years than BRCA2 mutation carriers (80.0% and 40.0%, respectively, 
p = 0.034).
Screening visits and events during follow-up
The total follow-up in this study was 5064 months (422 women years). The 
median follow-up was 24.0 months per woman (range 2 – 236 months). Women 
were censored because of preventive mastectomy (n = 32, 23.0%), breast cancer (n 
= 2, 1.4%), referral to another hospital (n = 7, 5.0%) or loss to follow-up (n = 10, 7.2%), 
the other women were still in screening after the end of our study (Table 2.2). 
In the women for whom screening ended after detection of breast cancer, one 
underwent mastectomy and one did not undergo further screening after being 
diagnosed with metastases after breast cancer in history.
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Table 2.1: Characteristics of the women at baseline (N = 139)
 BRCA1 (n = 88) BRCA2 (n = 51) Total (N = 139) Statistics
Age at RRSO in years
Median (range) 40.5 (30 – 51) 42.0 (33 – 51) 41.0 (30 – 51) p = 0.059
Previous breast cancer
  No 77.3% (68/88) 90.2% (46/51) 82.0% (114/139) p = 0.081
  Yes unilateral 15.9% (14/88) 9.8% (5/51) 13.7% (19/139)
    ≤ 45 years 85.7% (12/14) 40.0% (2/5) 73.7% (14/19) p = 0.034a
  Yes bilateral 6.8% (6/88) – 4.3% (6/139)
    ≤ 45 years 100% (6/6) – 100% (6/6)
Age at diagnosis first breast cancer in years (n = 25)
  Median (range) 40.0 (30 – 49) 46.0 (34 – 50) 41.0 (30 – 50) p = 0.143
Breast cancer therapy
  BCT unilateral 40.0% (8/20) 80.0% (4/5) 48.0% (12/25) p = 0.427
  Mast unilateral 40.0% (8/20) 20.0% (1/5) 36.0% (9/25)
  BCT bilateral 15.0% (3/20) – 12.0% (3/25)
  BCT and Mast 5.0% (1/20) – 4.0% (1/25)
HRT useb
  No 51.2% (41/80) 56.2% (27/48) 53.1% (68/128) p = 0.583
  Yes 48.8% (39/80) 43.8% (21/48) 46.9% (60/128)
ap < 0.05 is significant. Mann–Whitney U test for continuous variables, Pearsons’ χ2 test for proportions; 
bHormonal replacement therapy after RRSO.
Abbreviations: BCT is breast conserving therapy; Mast is mastectomy, if noted as BCT and Mast, 1 breast is 
treated with BCT and 1 with Mast.
Table 2.2: Follow-up
 BRCA1 (n = 88) BRCA2 (n = 51) Total (N = 139)
Follow-up in months
  Total 3621 1443 5064
  Median (range) 29.0 (2 – 236) 20.0 (2 – 143) 24.0 (2 – 236)
Prophylactic mastectomy 20.5% (18/88) 27.5% (14/51) 23.0% (32/139)
Screening ended after breast cancer 2.3% (2/88) – 1.4% (2/139)
Referral to other hospital 6.8% (6/88) 2.0% (1/51) 5.0% (7/139)
Lost to follow-up 9.1% (8/88) 3.9% (2/51) 7.2% (10/139)




In a total of 1,146 hospital visits, 1,191 screening modalities (CBE, MRI or 
mammography) were performed in 422 women years. During the total screening 
period, 14 new breast cancers were detected: 12 new tumours and 2 prevalent 
tumours, both within 6 months after RRSO. The median time between RRSO and 
detection of a new tumour was 16.5 months. Three patients with a new breast 
cancer had a history of breast cancer before RRSO. All of the 3 were contra-lateral 
new breast cancers, there were no local recurrences. In 6 of the 10 invasive 
cancers the lymph nodes were positive. One of the 2 interval cancers was node 
positive. Of the 14 women who were diagnosed with breast cancer after RRSO, 5 
used HRT. One of these breast cancers was an interval tumour.
Performance of the screening methods
The performance of the three screening modalities is summarized in Table 2.3. 
The overall sensitivity of the breast cancer screening program is 85.7%. Two 
tumours were interval cancers. No tumours were found by CBE (Table 2.3). This 
gives CBE a sensitivity of 0%, a specificity of 97.7%, a PPV of 0%, and a NPV of 
98.1. In 9 women with breast cancer after RRSO, mammography screening was 
conducted and 5 of the 9 cancers were identified by mammography. This gives 
mammography a sensitivity of 55.6%, a specificity of 98.4%, a PPV of 50.0%, and 
a NPV of 98.8%. In 10 women with breast cancer after RRSO MRI screening was 
conducted, 6 of these cancers were identified by MRI. This gives MRI a sensitivity 
of 60.0%, a specificity of 95.9%, a PPV of 35.3%, and a NPV of 98.5%.
Of the 2 interval tumours, the first (20 mm, node positive) was detected 
5 months after screening CBE. Mammography screening had not yet been 
performed. This was in 1999 and MRI was not yet part of the screening protocol 
at that time. Five years after diagnosis, this patient died of metastatic disease 
after a relapse in the mastectomy scar. The second interval cancer (11 mm, node 
negative) was detected by the patient herself 2 weeks after a negative CBE 
screening. MRI had not been conducted and the last mammography was 17 
months before the new tumour was found.
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Table 2.3: Performance of the screening tests
 Cancer present Cancer absent Total
CBE: 11 cancers (2 interval), 9 invasive, 2 DCIS
    Positive – 13 13
    Negative 11 559 570
    Total 11 572 583
  Sensitivity: 0% (95% CI 0 – 32%) PPV: 0% (95% CI 0 – 28%)
  Specificity: 97.7% (95% CI 96 – 99%) NPV: 98.1% (95% CI 97 – 99%)
Mammography BI-RADS ≥ III: 9 cancers (no interval), 7 invasive, 2 DCIS
    Positive 5 5 10
    Negative 4 316 320
    Total 9 321 330
  Sensitivity: 55.6% (95% CI 23 – 85%) PPV: 50.0% (95% CI 20 – 80%)
  Specificity: 98.4% (95% CI 96 – 99%) NPV: 98.8% (95% CI 97 – 100%)
MRI BI-RADS ≥ III: 10 cancers (no interval), 7 invasive, 3 DCIS
    Positive 6 11 17
    Negative 4 257 261
    Total 10 267 278
 Sensitivity: 60.0% (95% CI 27 – 86%) PPV: 35.3% (95% CI 15 – 61%)
 Specificity: 95.9% (95% CI 93 – 98%) NPV: 98.5% (95% CI 96 – 100%)
Total screening: 14 cancers (2 interval), 11 invasive, 3 DCIS
    Positive 12 28 40
    Negative 2 1149 1151
    Total 14 1177 1191
 Sensitivity: 85.7% (95% CI 56 – 98%) PPV: 30.0% (95% CI 17 – 47%)
 Specificity: 97.6% (95% CI 97 – 98%) NPV: 99.8% (95% CI 99 – 100%)
Abbreviations: DCIS is ductal carcinoma in situ; PPV is positive predictive value; NPV is negative predictive 
value.
Screening visits and additional investigation
Of the 139 women who attended screening after RRSO, 127 women had at least 
one screening CBE, 117 women had at least one screening mammography and 109 
women had at least one screening MRI (Table 2.4). The total number of screening 
investigations was highest for CBE (583), and lowest for MRI (278). CBE generated 
the least additional diagnostic procedures, 3% of the screening visits led to 
additional research. For MRI, 21% of the screening visits led to additional research 
and for mammography, 14% of the screening visits led to additional research. 
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In the study period, a total of 27 invasive diagnostic procedures (15 fine needle 
aspirations and 12 biopsies) were conducted, also most after MRI. Most additional 
diagnostic procedures were performed by using ultrasound (64 times).
Table 2.4: Screening visits and additional investigation
Screening modality Visits CBE Mammography MRI Ultrasound FNA Biopsy Total
  CBE (n = 127) 583 4 2 – 7 2 2 17
  Mammography (n = 117) 330 2 3 2 31 3 4 45
  MRI (n = 109) 278 5 4 5 27 10 6 57
Total 1191 11 9 7 64 15 12 118
Abbreviations: CBE is clinical breast examination, MRI is magnetic resonance imaging, FNA is fine needle 
aspiration.
While no new cancers where found with CBE, CBE was carried out as additional 
investigation 11 times. Of the tumours found during the screening period, 5 were 
palpable when CBE was carried out after suspect findings at mammography or 
MRI. In 3 of these cases, the women had had a negative CBE screening in the 
month before the suspect findings.
When screening consisted of MRI and mammography, 43 screening visits 
were needed to find one new breast cancer. When CBE was added to the screening, 
85 screening visits were needed to find one new breast cancer.
Discussion
In this group of 139 BRCA1/2 mutation carriers who had had RRSO at a 
premenopausal age and were under surveillance at our Family Cancer Clinic, 
14 breast cancers were detected in 14 women during 442 women years. There 
were 2 prevalent, 10 screen detected and 2 interval breast cancers. The program 
sensitivity was 85.7% and the specificity 97.5%. For the individual screening 
modalities, the sensitivity for CBE was 0% (95% CI 0 – 32.1%), for mammography 
55.6% (95% CI 22.7 – 79.9%), and for MRI 60.0% (95% CI 27.4 – 86.3%). Of all these 
cancers, 70% was high grade (III) and 60% of the tumours were node positive.
The program sensitivity of screening with MRI, mammography, and CBE was 
85.7% (95% CI 56.2 – 97.6%). Earlier studies on screening effectiveness in women at 
high risk of breast cancer found sensitivities varying from 91.1% to 97.7%, which 
seems to be higher (163,170,173,175). Only one study on the long-term effectiveness 
of the MRISC study found a total program sensitivity of 86.6% (164). The study 
population in these previous studies was more diverse, consisting of pre- and 
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postmenopausal women. Also, their studies contained mutation carriers, but also 
women at high risk for breast cancer without mutation. In our study, all women 
were postmenopausal after premenopausal RRSO and they were all mutation 
carriers. These factors may have contributed to the differences in effectiveness.
Both Kriege et al. and Rijnsburger et al. present results of the MRISC study. Of 
the 2,275 participants in these studies, 148 were from our family cancer clinic 
(164). Kriege et al. noted that 19% of the mutation carriers had RRSO in history 
(163). The amount of women analysed in both the MRISC study and our study is 
probably small.
A main factor that might have contributed to the lower sensitivity of 
our surveillance program is that we evaluated the program sensitivity of 
the screening over a period of 14 years (1995 – 2009) during which screening 
guidelines changed several times. MRI was offered from 1999 to a subset of 
women as part of the MRISC study, and as of 2005 it is offered to all women at 
high risk. One interval cancer was found in 1999. Excluding this tumour from 
the analysis, would increase the program sensitivity of our screening from 85.7% 
to 91.7%, which is in the range that can be expected. Another consideration is 
that the four series mentioned are prospective studies with a strict screening 
protocol in which every woman receives MRI, mammography, and CBE at 
regular intervals (163,170,173,175). In daily practice, many factors may influence 
the regularity of the screening visits. Planning MRI, mammography, and CBE 
on the first visit is sometimes difficult because of agenda and capacity issues, 
women do not always attend appointments, or there may be contra-indications 
for MRI scanning. It is reasonable to assume that the second interval cancer is 
related to “protocol deviances.” This interval cancer was detected by the patient 
herself, two weeks after a negative CBE screening, and her last mammography 
was 17 months before the new tumour was found. Though this woman was in 
screening from 2005 to 2007, she was not screened by MRI.
For the separate screening modalities, the sensitivity of 0% (95% CI 0 – 32.1%) 
for CBE found in our study was comparable to sensitivities of 9.1 – 17.8% found 
in other studies (163,170). In general, CBE is considered to have no additional 
benefit over mammography, whereas it does increase the false positive rate 
(253,254). When CBE was excluded from program sensitivity analyses, sensitivity 
did not change. This would mean exclusion of 538 CBE screening visits in which 
no new tumours were detected. Three of the new tumours found by imaging 
were palpable at diagnosis (CBE was conducted as additional research), while 
CBE screening within the month before diagnosis was negative. Also, CBE has 
proven to be useful in detecting loco-regional recurrences and contralateral 
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breast cancer in an early stage in women with breast cancer in history (e.g. after 
mastectomy, breast conserving therapy, and radiotherapy) (255). This indicates 
that CBE should not be eliminated from our post-RRSO screening protocol, 
especially in women with previous breast cancer.
The sensitivity of 55.6% (95% CI 22.7 – 79.9%) for mammography was not 
significantly different from sensitivities of 32 – 40% reported in previous studies 
(163,170,173,175). Long-term follow-up in the MRISC study revealed a sensitivity 
for mammography of 25% in BRCA1 mutation carriers (164). This is much lower 
than the sensitivity found in our study, while the majority of tumours we found, 
were also in BRCA1 mutation carriers. Due to the lower breast density after RRSO, 
we expected that the sensitivity of mammography in our population would be 
higher than in other high risk screening studies. The sensitivity of mammography 
we found was indeed higher than previously reported though the difference was 
not significant. This may be due to small numbers, or to the fact that about 47% 
of the women used HRT after RRSO, which is known to preserve breast density in 
postmenopausal women (256).
The sensitivity of 60.0% (95% CI 27 – 86%) for MRI in our study was lower 
(though not significantly) than the sensitivities for MRI reported in previous 
studies, ranging from 71.1 to 77.0% (163,170,175) and significantly lower than the 
sensitivity of 90.7% for MRI found by Kuhl et al. (173). It is reasonable to suppose that 
the effectiveness of MRI screening in daily practice is less than the performance 
of MRI screening in prospective trials. At our centre, MRI software, protocols, and 
scanners evolved in the past years. It is likely that MRI sensitivity will improve in 
the future along with experience and further improvement of MRI technology. 
Another issue is that, 2 of the 4 tumours that where false negative on MRI were 
full ductal carcinoma in situ (DCIS). Most tumours missed on MRI in the MRISC 
study were also DCIS, which indicates that MRI is significantly less reliable in 
detecting DCIS (254). This is illustrated by the fact that for invasive tumours only, 
MRI sensitivity in our study is 75%, which lowers to 60.0% (95% CI 27.4 – 86.3%) 
when DCIS are included. Rijnsburger et al. found an MRI sensitivity of 66.7% 
for BRCA1 mutation carriers and 69.2% for BRCA2 mutation carriers, which was 
significantly higher than the sensitivity of 25% they found for mammography. 
In addition, they showed that MRI enabled the detection of breast tumours in a 
more favourable stage than mammography. They suggest that MRI screening 
should be considered biannually in certain categories (164).
In our study, tumour size was also comparable to other studies, with 83.3% 
of the tumours after RRSO being smaller than 20 mm, compared to percentages 
ranging from 75 to 94% in other studies. However, 60% of the tumours in our 
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study were node positive, while others found percentages of 15.4 – 36.0% 
(163,170,173,175). These findings need further evaluation.
This is the first study on the effectiveness of breast cancer screening with 
CBE, mammography, and MRI, in BRCA1/2 mutation carriers who had undergone 
RRSO at premenopausal age, conducted in daily practice and not in the context 
of a clinical trial. It is an interesting finding that MRI sensitivity in this study 
was slightly lower than MRI sensitivity in earlier trials. The question is if this 
difference is caused by protocol deviances in general practice or by effects 
generated by RRSO. Also, mammography sensitivity seems to be higher after 
RRSO than before. This might be caused by lower breast density after RRSO, but 
this should be evaluated during long term follow-up. We used the number of new 
tumours detected by screening to evaluate the effectiveness of the surveillance 
program. Eventually, the purpose of screening is to increase survival after breast 
cancer. For evaluating the effect of survival, long term follow-up is needed. We 
continue to collect data of this study population in a prospective database.
To conclude, the sensitivity of three-modality breast cancer screening in 
BRCA1/2 mutation carriers after RRSO is lower than breast cancer screening 
before RRSO. It is the lower sensitivity of MRI that contributed largely to the lower 
sensitivity of the total screening program, while mammography sensitivity 
increases after RRSO. In our post RRSO population, CBE did not contribute to 
tumour detection. Our findings suggest that intensive breast cancer screening 
with both MRI and mammography should be continued in BRCA1/2 mutation 
carriers, after RRSO.
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